



LucidQuest Intelligence
Accelerate your success



AAD 2026 Preview – Table of Contents

• <u>General Overview and Conference Themes</u>	<u>3-5</u>
• <u>Noteworthy Scientific presentations at AAD'26</u>	<u>5-38</u>
• <u>Key Topics From Notable Presentations</u>	<u>6-7</u>
• <u>Focus of Key Industry Sponsored Sessions at AAD'26</u>	<u>8-11</u>
• <u>Notable Presentations at AAD'26</u>	<u>12-36</u>
• <u>Key Sponsored Sessions Information</u>	<u>37-39</u>
• <u>Noteworthy AI / ML Presentations</u>	<u>40-47</u>
• <u>Key AI / ML Themes</u>	<u>41-42</u>
• <u>Key AI/ML Presentations Information</u>	<u>43-47</u>
• <u>Get in touch with LucidQuest</u>	<u>48</u>



AAD 2026 – General Overview

- ➔ • **Flagship forum:** AAD 2026 is set to be a leading global dermatology meeting in Denver, uniting clinicians, researchers, educators, and industry
- ➔ • **Broad coverage:** The meeting is expected to cover the full dermatology landscape, from clinical updates to translational, basic, and population-level research
- ➔ • **Research-first format:** Data are poised to feature across posters, symposia, gross and microscopic sessions, and late-breaking oral presentations
- ➔ • **Clinical focus:** The conference is likely to highlight novel, practice-relevant findings with near-term treatment impact
- ➔ • **Extensive learning:** Attendees are expected to access a large session portfolio, including on-demand content beyond the live meeting
- ➔ • **Collaboration hub:** AAD 2026 is set to support affiliate meetings, networking, and broad professional exchange



AAD 2026– Conference Themes



- **Inflammatory disease evolution:** Inflammatory dermatoses are likely to remain central, with focus on translational advances, disease heterogeneity, and refined management across complex patient populations
- **Hidradenitis suppurativa momentum:** HS is expected to stand out as a priority area, reflecting growing interest in spectrum-based disease management and unmet therapeutic need
- **JAK inhibitor positioning:** Targeted immunomodulation is poised to be a major theme, especially around selecting appropriate dermatology candidates for JAK inhibitor therapy
- **Diagnostic sophistication:** Advanced dermoscopy is likely to feature prominently, signaling continued interest in earlier detection and more accurate lesion-level assessment
- **Practice-changing late breakers:** Late-breaking sessions are expected to spotlight clinical trials, biomarkers, transformative technologies, and innovative basic science with immediate field impact

Noteworthy Scientific presentations at AAD 2026





Key Topics From Notable Presentations (1/2)

- ✓ • **Atopic dermatitis, eczema, urticaria, pruritus, and barrier disorders:** AAD 2026 is set to spotlight a crowded late-stage pipeline in AD and itch, with REMIX-1/2, TRACE, ARCADIA, COAST 1/2, SHORE, RADIANT-AD, and APEX expected to frame competition around durability, real-world effectiveness, and broader symptom control
- ✓ • **Psoriasis, hidradenitis suppurativa, vitiligo, lupus, and other inflammatory dermatoses:** Inflammatory disease sessions are poised to emphasize trial maturity and label expansion, with ICONIC-LEAD, ONWARD 1/2, LATITUDE-PsO-3001/3002, STOP-HS1/2, SUNSHINE/SUNRISE, Viti-Up, TOGETHER-PsA, and AMETHYST Part A expected to anchor psoriasis, HS, vitiligo, and CLE discussions
- ✓ • **Hair, scalp, nail, acne, rosacea, pigmentary, and aesthetic dermatology:** Hair and aesthetic dermatology are likely to center on JAK-driven alopecia areata momentum and procedural optimization, with THRIVE-AA1/2 and ALLEGRO expected to lead efficacy narratives, while acne, melasma, and injectables sessions are set to highlight longer-term tolerability and technique refinement



Key Topics From Notable Presentations (2/2)

- ✓ **Skin cancer, precancers, dermatologic surgery, and oncologic diagnostics:** Skin cancer content is expected to combine epidemiology, surgical benchmarking, and technology validation, with INTASYL PH-762, the Multicenter Selective Lymphadenectomy Trial-I revisit, and Veterans Affairs keratinocyte carcinoma chemoprevention follow-up poised to shape melanoma, carcinoma, and Mohs-related discussions
- ✓ **Autoimmune blistering, connective tissue, genodermatoses, rare disorders, and wound care:** Rare and immune-mediated dermatoses are set to emphasize unmet need and specialty innovation, with PIONEER and INSPIRE expected to stand out alongside phase 3 infantile hemangioma data, while blistering disease, ichthyosis, epidermolysis bullosa, and DRESS studies are likely to deepen comorbidity understanding
- ✓ **Dermatology practice, disparities, education, epidemiology, and miscellaneous topics:** Practice-focused sessions are expected to highlight access, education, and digital implementation rather than drug development, with SkinTracker, Patient Finder, reflectance confocal microscopy, and global access studies poised to show how dermatology workflows, literacy, and equity frameworks are evolving



Focus of Key Industry-Sponsored Sessions at AAD 2026 (1/4)



• Eli Lilly:

- Focus Areas: Atopic dermatitis and psoriasis lifecycle strategy
- Sessions are likely to emphasize long-term disease control with EBGLYSS® (lebrikizumab-lbkz) in moderate-to-severe atopic dermatitis, alongside Taltz® (ixekizumab) positioning and combination-use discussion with Zepbound® (tirzepatide) in psoriatic disease and obesity-related management



• AbbVie:

- Focus Areas: Advancing efficacy expectations in immunodermatology
- The AbbVie sessions are set to reinforce high-treatment-goal positioning in inflammatory skin disease, likely emphasizing clearer skin targets, stronger response expectations, and competitive differentiation within the branded dermatology portfolio



Focus of Key Industry-Sponsored Sessions at AAD 2026 (2/4)

- **Galderma:**

- Focus Areas: Neuroimmune itch signaling in dermatology
- The company is set to spotlight the IL-31 neuroimmune pathway, likely framing itch biology, patient burden, and pathway-targeted management as key themes in inflammatory skin disease care

- **Thermo Fisher Scientific:**

- Focus Areas: Translational immunology and Treg biology
- Sessions are expected to connect discovery science with clinical dermatology by emphasizing regulatory T cells as a mechanistic and therapeutic focus in inflammatory skin disorders



Focus of Key Industry-Sponsored Sessions at AAD 2026 (3/4)

- **Sanofi:**

- Focus Areas: Early inflammatory mechanisms in atopic dermatitis
- Discussions are poised to explore the inflammatory “prequel” in AD, emphasizing upstream disease biology, early intervention concepts, and scientific framing for targeted treatment strategy

- **Doximity:**

- Focus Areas: Generative AI and workflow efficiency in dermatology practice
- The session is expected to highlight Doximity GPT for documentation, communication, and productivity, positioning AI as a practical tool for clinical workflow optimization rather than direct therapeutics



Focus of Key Industry-Sponsored Sessions at AAD 2026 (4/4)

- **Novartis:**

- Focus Areas: Chronic spontaneous urticaria and new approved therapy uptake
- Presentations are expected to focus on the newly approved RHAPSIDO® (remibrutinib), highlighting its role in CSU management, clinical adoption, and differentiation within the advanced urticaria treatment landscape

- **Pelthos Therapeutics:**

- Focus Areas: Active treatment of molluscum contagiosum
- The company is poised to highlight Zelsuvmi™ (berdazimer) topical gel, 10.3%, challenging watchful waiting and positioning topical nitric oxide-based therapy as a more intervention-focused management approach



Notable Presentations And Late-breaking Sessions At AAD 2026

Notable Presentations Information At AAD 2026



Autoimmune blistering, connective tissue, genodermatoses, rare disorders, and wound care (1/4)

Date	Author	Title
27 March 2026	Jessica Muha MSc	Incidence of Systemic Malignancies in Localized and Systemic Scleroderma in Quebec, Canada: A Population-Based Study
28 March 2026	Jessica Saoub BS	Comparative Outcomes of Immunomodulatory Versus Conventional Therapies in Congenital Ichthyosis: A TriNetX Cohort Study
28 March 2026	Karin Hartmann	Avapritinib Achieves Durable Improvement in Skin Findings With a Well-Tolerated Safety Profile in Patients With Indolent Systemic Mastocytosis (ISM): Long-term Analyses From the PIONEER Study
28 March 2026	Dustine Reich BS and Shari Lipner MD	Pemphigus is associated with osteoporosis and impacted by corticosteroid use in a large retrospective cohort study using TriNetX
28 March 2026	Gaurav Pathak PharmD	Risk of malignancies in patients with bullous pemphigoid; a case-control study
28 March 2026	Sanjeev Handa MD	Comparision of clinical, immunological and therapeutic response in gliptin associated versus idiopathic bullous pemphigoid - a prospective study
28 March 2026	Maureen Whittelsey BS	EFFICACY AND SIDE EFFECTS OF JANUS KINASE INHIBITORS IN CUTANEOUS GRAFT-VERSUS-HOST DISEASE: A RETROSPECTIVE COHORT STUDY
28 March 2026	Olivia Guidotti B.A.	Comparison of peripheral T-cell lymphoma patients with and without erythrodermic manifestations: A single center retrospective cohort study



Notable Presentations Information At AAD 2026



Autoimmune blistering, connective tissue, genodermatoses, rare disorders, and wound care (2/4)

Date	Author	Title
28 March 2026	Nicole Chin BA	Risk of Metabolic and Joint Disease in Congenital Ichthyosis: A Case-Control Study in the All of Us Research Program
28 March 2026	Amy (Dickey) Yeung	Efficacy and Safety of Dersimelagon in Adults and Adolescents with Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP): Top-line Results from the INSPIRE Phase 3 Randomized Clinical trial
28 March 2026	yi tian	Efficacy and safety of timolol maleate 0.5% gel for the treatment of proliferative superficial infantile hemangioma: A multicenter, randomized, double-blind, controlled, phase 3 trial
28 March 2026	Sahithi Talasila	Increased Risk of Cutaneous T-Cell Lymphoma and Metastasis in Dupilumab-Treated Patients Across All Approved Indications: A Retrospective Cohort Study
29 March 2026	Pooja Shet BA	Topical Timolol as an Adjunct to Standard Care for Diabetic Foot Ulcers: A Randomized Controlled Trial
All days	Amit Singal	Pityriasis Rosea is Not Associated with Increased Risk of Pregnancy Complications in a Large Population-based Cohort Study
All days	Aliya Shabbir BS	Clinical Characterization and Therapeutic Outcomes for Treatment of Taxane-Induced Sclerosis: A Retrospective Cohort Study
All days	Jessica Saoub BS	Comparison of Systemic and Topical Retinoids and the Association of Inflammatory Bowel Disease in Ichthyosis Patients: A Population-Based Cohort Study



Notable Presentations Information At AAD 2026



Autoimmune blistering, connective tissue, genodermatoses, rare disorders, and wound care (3/4)

Date	Author	Title
All days	Michael Tang MD	Clinical Findings in Cryptococcoid Neutrophilic Dermatitis: A Review of Literature and Single-Center Retrospective Study
All days	Wan-Chen Lin MD	Treatment of drug reaction with eosinophilia and systemic symptoms with tofacitinib: a pilot study with dynamic cytokines profiles investigation
All days	Dylan Wambold B.S	Quantifying Dermatological Comorbidities in Ehlers-Danlos Syndromes: A U.S. National Study on Follicular Occlusion Disorders
All days	Maria Vazquez-Machado BS	VIRTUAL REALITY FOR PAIN MANAGEMENT IN PATIENTS WITH CONNECTIVE TISSUE DISEASE UNDERGOING HAND BOTULINUM TOXIN INJECTIONS: A PILOT STUDY
All days	Chaw-Ning Lee MD	Global Epidemiology Of Disease Burden And Comorbidity Study of Pediatric Patients With Different Subtypes Of Epidermolysis Bullosa
All days	Dustine Reich BS and Shari Lipner MD	Bullous pemphigoid is associated with osteoporosis and vertebral fracture risk in a large retrospective cohort study using TriNetX
All days	Brigitte Cochran DO	Epidermolysis Bullosa and Emergent Intubation Outcomes: A Large Database Retrospective Cohort Study
All days	Mary Cavanagh MD	Comparative Incidence of Bullous Pemphigoid in Patients Treated with DPP-4 Inhibitors Versus Metformin: A Retrospective Cohort Study



Notable Presentations Information At AAD 2026



Autoimmune blistering, connective tissue, genodermatoses, rare disorders, and wound care (4/4)

Date	Author	Title
All days	Gaurav Pathak PharmD	Triggers for epidermolysis bullosa acquisita flares: A multi-database retrospective pharmacovigilance study
All days	Gaurav Pathak PharmD	Mucous membrane pemphigoid in the United states: A cross-sectional study of the All of Us database
All days	Eli Kasher BS and Janellen Smith MD	Increased Risk of Bullous Pemphigoid Among Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Cohort Study
All days	Jordan Talia MD	Association between Systemic Sclerosis and the Development of Non-Infectious Granulomatous Dermatoses and Lichen Planus: A TriNetX Database Study
All days	Lana Salloum	Characterizing epidemiology and demographics of DRESS Syndrome: Insights from a large cohort study
All days	Ursula Biba BS	Differences in the Clinical Features, Treatments, and Organ Involvement of DRESS by RegiSCAR Score: A Retrospective Cohort Study



Notable Presentations Information At AAD 2026



Dermatology practice, disparities, and miscellaneous topics (1/4)

Date	Author	Title
28 March 2026	Cecilia Deantonio	Multi-Omics analysis of SAR445399, an IL-1R3 antagonist: anti-inflammatory effects in skin challenges from Phase 1 study
28 March 2026	C. Ray Cheever BS	Risk of Psychiatric Disorders Following Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Retrospective Database Study
28 March 2026	Sofia Milosavljevic BA	Interpreter Service Disparities in Dermatology: A National Cross-Sectional Study
28 March 2026	Jacob Fay B.S.	Brass Musicians and Instrument-Related Dermatoses: National Survey Results
28 March 2026	Olivia Ueltschi	Myths of Minoxidil: A Survey Study
28 March 2026	Amanda Gong BS	People with HIV Have an Increased Risk of Inflammatory Dermatologic Conditions: A Large Propensity-Matched Retrospective Cohort Study
28 March 2026	Miranda Chen	Understanding mentorship needs in dermatology: A qualitative study of faculty and resident perspectives
29 March 2026	Steven Daniel Daveluy	Intro to the Project, Overview of Patient Finder and Results



Notable Presentations Information At AAD 2026



Dermatology practice, disparities, and miscellaneous topics (2/4)

Date	Author	Title
29 March 2026	Iltefat H. Hamzavi	John Kenney Jr., MD Lifetime Achievement Award and Lectureship: Running to the Pain:How Dermatology offers Hope and Results
30 March 2026	Esther Ellen Freeman	Mapping Access to Care Worldwide: the Skin Health Observatory Study
30 March 2026	Eingun James Song	The Devil Is in the Details: Understanding JAK Trial Populations and Real-World Risk
All days	Emiliya Akhundova BA	Comparative Study of Dermatologic Skin Color Classification Scales
All days	Randy Ko MS4	Evaluating the Long-term Impact and Clinical Relevance of Reflectance Confocal Microscopy in Dermatology: A Retrospective Study
All days	Noah Danesh MPH	Association of Smoking and Second-Hand Smoke Exposure with Epidermal Cysts: A Retrospective Study
All days	Anagha Thiagarajan BS	Improving Dermatologic Health Literacy: A Study of Large Language Models and Readability Optimization
All days	Radhika Gupta BS	Remote Photo-Monitoring in Clinical Research Using the SkinTracker Mobile-App: A Pilot Study in Atopic Dermatitis and Psoriasis



Notable Presentations Information At AAD 2026



Dermatology practice, disparities, and miscellaneous topics (3/4)

Date	Author	Title
All days	Bianca Sanabria MD	Assessing GPT's Ability to Generate Visual Patient Education Materials in Pediatric Care: A Proof of Concept Study
All days	Nicholas Schell MCIT	Assessing the Effectiveness of ChatGPT as a Study Tool for the Dermatology CORE Exam
All days	Angela Loczi-Storm BS	TikTok's Take on the Dermatology Match: A Qualitative Study of TikTok Match Advice and Its Alignment with Applicant Ranking Factors Reported in the 2024 NRMP Program Director Survey
All days	Marissa Yaldo	Exploring Skin Cancer Education Preferences among Solid Organ Transplant Recipients: A Survey Study
All days	Daniela Barata Herrera BS	Multimodal Sun Protection Education for the Organ Transplant Recipient: Longitudinal Study
All days	Aisha Ayub	Representation of Skin of Color in Medical Student Board Preparation: A Multi-edition Content Analysis of a Widely Used Study Text
All days	Jessica Saoub BS	Sun Safety Knowledge, Behaviors, and Skin Cancer Awareness Among Hispanic Student Athletes: A Descriptive Cross-Sectional Study
All days	Jaden Troxel	Enhancing Melanoma Patient Education Through Animation: A Prospective Study of Patient Comprehension and Anxiety



Notable Presentations Information At AAD 2026



Dermatology practice, disparities, and miscellaneous topics (4/4)

Date	Author	Title
All days	Alana Sadur BS	A Multi-Center Study of Patient Perspectives and Knowledge of Integrative Dermatology
All days	Michelle Cheng PhD	Racial Disparities in Fluctuating Skin: Impact on Quality of Life from an Epidemiological Study
All days	Samruddhi Nandkumar Borate MPharm	Direct Health Care Expenditures and Health-Related Quality of Life in Patients with Psoriasis: Results from the Medical Expenditure Panel Survey, 2020-2023
All days	Abizairie Sánchez-Feliciano BS	Comparing the measurement properties, informativity and responsiveness of the Dermatology Life Quality Index (DLQI), DLQI-Relevant (DLQI-R), and Skindex-29 in patients with chronic skin disease: A prospective cohort study
All days	Julian Cortes BS	Chronic Spontaneous Urticaria is an Independent Predictor of Atherosclerotic Cardiovascular Disease: A Population-Based Study
All days	Valeria Torres García MS	Alternative Dermatologic Care-Seeking Behavior in an Underserved Population: A Cross-Sectional Study in Puerto Rico





Notable Presentations Information At AAD 2026

Atopic dermatitis, eczema, urticaria, and barrier disorders (1/4)

Date	Author	Title
27 March 2026	Mark Lebwohl	A pooled analysis of the hemostatic safety profile of remibrutinib over 24 weeks in patients with chronic spontaneous urticaria from the REMIX-1 and REMIX-2 phase 3 studies
27 March 2026	April W. Armstrong	Real-world effectiveness of 12 months tralokinumab treatment in patients with skin of color and moderate-to-severe atopic dermatitis: Final data from the prospective, non-interventional, international, TRACE study
27 March 2026	Naomi Matsuno BS	Comparative outcomes of pruritus in hemodialysis and peritoneal dialysis: an observational retrospective cohort study
27 March 2026	Maria Schneeweiss	Comparative risk of infections in children with atopic dermatitis who started dupilumab vs. topical therapies: a nationwide propensity-score matched cohort study
28 March 2026	Eric Simpson	Patient-perceived factors associated with Chronic Hand Eczema– Results from the CHECK study in the United States
28 March 2026	Sarina B Elmariah	Patients with prurigo nodularis treated with dupilumab experience significant improvement in quality of life and sleep: 6-month results from the RELIEVE-PN study
28 March 2026	Waleed Adawi MD	Decreased cardiovascular risk in prurigo nodularis patients treated with dupilumab: A propensity-matched global study
28 March 2026	Sohail Chaudhry MD	Novel Regulatory T-cell enhancing Biologic Rezpegaldesleukin: Phase 2b Efficacy, Safety, and Baseline Severity-Dependent Treatment Response in Moderate-to-Severe Atopic Dermatitis

Notable Presentations Information At AAD 2026



Atopic dermatitis, eczema, urticaria, and barrier disorders (2/4)

Date	Author	Title
28 March 2026	Silvia Mariel Ferrucci	Dupilumab Shows Sustained Effectiveness and Safety in Patients With Atopic Dermatitis: Real-World Insights From the Overall Population 3 Years Into the GLOBOSTAD Multinational Prospective Observational Study
28 March 2026	Diamant Thaçi	Long-term (up to 104 weeks) maintenance of itch and skin responses with nemolizumab treatment in patients with moderate-to-severe atopic dermatitis – Post hoc analyses from the ARCADIA long-term extension trial
28 March 2026	Dylan Wambold B.S and Connor Kim B.S	Impact of GLP-1 and Dual GLP-1/GIP Receptor Agonists on Inflammatory Outcomes in Atopic Dermatitis: A Real-World Cohort Study
28 March 2026	April W. Armstrong	Real-world effectiveness of 12 months tralokinumab in 495 adult atopic dermatitis patients with hand and feet involvement: Final data from the prospective, non-interventional, international, TRACE study
28 March 2026	Eric Lawrence Simpson	Combined Oral: Efficacy and Safety of Monotherapy Amlitelimab, a Non-Depleting Anti-OX40 Ligand Antibody, in Moderate-to-Severe Atopic Dermatitis: 24-Week Results From the Pivotal COAST 1 and COAST 2 Phase 3 Trials and Efficacy and Safety of Amlitelimab, a Non-Depleting Anti-OX40 Ligand Antibody, in Combination With Topical Therapy in Participants With Moderate-to-Severe Atopic Dermatitis: 24-Week Results From the SHORE Phase 3 Trial
28 March 2026	Jianzhong Zhang	Long-term efficacy and safety of MG-K10 for moderate-to-severe atopic dermatitis: 52-week results from a pivotal phase 3 trial
28 March 2026	Mahta Mortezaei	Clinical Activity and Safety of KT-621, an Oral STAT6 Degradar, in Moderate-to-Severe Atopic Dermatitis: Phase 1b Trial Results
28 March 2026	Robert Bissonnette	Efficacy and Safety of Abrocitinib in Patients with Chronic Hand Eczema: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial





Notable Presentations Information At AAD 2026

Atopic dermatitis, eczema, urticaria, and barrier disorders (3/4)

Date	Author	Title
28 March 2026	Li Ye	Study on the Mechanism of Bifid Yeast Fermentation Product in Improving Pruritus of Middle-Aged and Elderly Dry Sensitive Skin
28 March 2026	Cheng Zhou	Rademikibart monotherapy in adult and adolescent patients with moderate-to-severe atopic dermatitis (AD): A 1-year, phase III, randomized, double-blinded, placebo-controlled trial (RADIANT-AD)
28 March 2026	Emma Guttman	Zumilokibart (APG777) Provides Early and Sustained Improvements in the Signs and Symptoms of Atopic Dermatitis: Results from the Phase 2 APEX Part A Study
28 March 2026	-	Efficacy and Safety of TQH2722 for the Patients with Atopic Dermatitis: 16-weeks Results from a Phase 3, Randomized, Placebo-controlled Study
28 March 2026	Xing-Hua Gao	Results of a Multicenter, Randomized, Double-Blind, Controlled Phase 3 Study of LP-003 Injection in H1 Antihistamine-Inadequately Controlled Chronic Spontaneous Urticaria (CSU)
29 March 2026	Isha Gandhi BS	The Gut Microbiome and Idiopathic Urticaria: A Mendelian Randomization Study
29 March 2026	Jordan Hill BS	Immune Checkpoint Inhibitor-Eczema: Results from a Multi-Institutional Cohort Study
29 March 2026	Hailey Olds MD	Omega-3 Supplementation and Risk of Eczematous Dermatitis in Patients Receiving Isotretinoin: Findings From a Prospective Cohort Study





Notable Presentations Information At AAD 2026

Atopic dermatitis, eczema, urticaria, and barrier disorders (4/4)

Date	Author	Title
30 March 2026	Gil Yosipovitch	A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus
All Days	Tonya Winders	Out-of-pocket expenses in patients with chronic inducible urticaria: Results from Urticaria Voices study
All Days	Jenna Currier B.A.	A Retrospective Cohort Study: The Efficacy of Omalizumab in Treating Chronic Idiopathic Urticaria and Concomitant Atopic Dermatitis
All Days	Raj Chovatiya	Health-related quality of life in people with Chronic Hand Eczema - Results from the CHECK study in the United States
All Days	Shawn G Kwatra	Patients with prurigo nodularis treated with dupilumab experience significant improvement in itch and nodule clearance: 6-month results from the RELIEVE-PN study

Notable Presentations Information At AAD 2026



Psoriasis, vitiligo, lupus, and other inflammatory dermatoses (1/4)

Date	Author	Title
27 March 2026	Bryce T. Roberts B.S.	Deucravacitinib in the Treatment of Pityriasis Rubra Pilaris: A Phase 2 Clinical Trial
27 March 2026	April Armstrong	Flare Prevention and Safety of Secukinumab vs Bimekizumab in Hidradenitis Suppurativa: A Matched Adjusted Indirect Comparison Analysis of Phase 3 Trials
27 March 2026	Dev Patel	Clinical Characteristics, Comorbidities, and Anatomic Features of Pediatric Vitiligo: An Interim Analysis from a Clinical Multi-Center Retrospective Study
27 March 2026	Jennifer Soung	Durability of Icotrokinra (Targeted Oral Peptide) Effects in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Study
27 March 2026	Jianzhong Zhang	Efficacy and Safety of Roflumilast Cream 0.3% in Chinese Adult and Pediatric Patients with Plaque Psoriasis: Results From a Phase 3 Trial
27 March 2026	Aaron Mangold	Sarcoidosis 2026 Update and New Trials
28 March 2026	Eli Kasher BS and Janellen Smith MD	Association of GLP-1 Therapy with Reduced Biologic Initiation in Hidradenitis Suppurativa: A Retrospective Cohort Study
28 March 2026	Seo Won (Anna) Cho BS	Persistent Risk of Venous Thromboembolism in Hidradenitis Suppurativa Despite Biologic Therapy: A Retrospective Cohort Study



Notable Presentations Information At AAD 2026



Psoriasis, vitiligo, lupus, and other inflammatory dermatoses (2/4)

Date	Author	Title
28 March 2026	Gabriela Palma BS	<u>Early Biologic Intervention in Childhood Psoriasis May Prevent Psoriatic Arthritis: A Population-Based Study</u>
28 March 2026	Sophia Manduca BS	<u>COVID-19 Infection Increases Risk of Systemic Lupus Erythematosus While Vaccination Decreases Risk: A Population-Based Cohort Study</u>
28 March 2026	Jennifer Soung	<u>Early and Durable Improvements in Patient-Reported Outcomes With the Targeted Oral Peptide Icotrokinra in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Study</u>
28 March 2026	Mark Lebwohl Professor	<u>Bimekizumab safety and sustained long-term efficacy in patients with active psoriatic arthritis and baseline psoriasis: Up to 3-year results from two phase 3 studies</u>
28 March 2026	Joseph F. Merola Professor	<u>Bimekizumab treatment resulted in long-term maintenance of complete clinical resolution across skin, joint, and nail domains in patients with active psoriatic arthritis: 3-year results from two phase 3 studies</u>
28 March 2026	April Armstrong	<u>Bimekizumab on-treatment remission as defined by the National Psoriasis Foundation: 1-year results versus ustekinumab and secukinumab in patients with moderate to severe plaque psoriasis</u>
28 March 2026	Jinhua Xu	<u>A Randomized, Double-blind, Dose-Escalation, Placebo-Controlled Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1139 for Patients with Moderate-to-Severe Plaque Psoriasis</u>
28 March 2026	Eingun James Song	<u>Quality of Life Improvements in Patients with Genital or Scalp Psoriasis Receiving Risankizumab: 16-Week Results from the UnIMMited Randomized Placebo-Controlled Trial</u>



Notable Presentations Information At AAD 2026



Psoriasis, vitiligo, lupus, and other inflammatory dermatoses (3/4)

Date	Author	Title
28 March 2026	Andrew Blauvelt	Envudeucitinib (ESK-001) in moderate-to-severe plaque psoriasis: 24-week results from the randomized, double-blind, active comparator- and placebo-controlled, Phase 3 ONWARD 1 and 2 studies
28 March 2026	Thierry Passeron	Efficacy and Safety of Upadacitinib in Adolescents and Adults for Treatment of Non-Segmental Vitiligo: Results of Two Phase 3 Studies (Viti-Up)
28 March 2026	NA	Safety Outcomes of IL-23 Versus IL-17 Inhibitors in Psoriasis: A Multicenter Real-World Study
28 March 2026	Ahmed Nassar	Emerging Inflammatory Biomarkers of Subclinical Synovitis in Psoriasis: A Case-Control Study
28 March 2026	Shanti Mehta	Glucose intolerance as a marker of disease activity in hidradenitis suppurativa: A retrospective cohort study
28 March 2026	Joseph Merola	Concomitant therapy with ixekizumab plus tirzepatide in adults with psoriatic arthritis and overweight or obesity demonstrated superior disease control compared to ixekizumab alone: results from the Ph3b TOGETHER-PsA trial
28 March 2026	Brett King	Targeting IL-15 with ordesekimab depletes cytotoxic CD8+ memory T cells and, in combination with phototherapy, results in greater repigmentation of vitiligo compared to placebo
28 March 2026	Melinda Gooderham	Once-daily Oral Zasocitinib Demonstrates Rapid and Reproducible Skin Clearance with a Consistent Safety Profile in Moderate-to-Severe Plaque Psoriasis: Results from Two Randomized Phase 3 Trials (LATITUDE-PsO-3001 and 3002)



Notable Presentations Information At AAD 2026



Psoriasis, vitiligo, lupus, and other inflammatory dermatoses (4/4)

Date	Author	Title
28 March 2026	Martina J. Porter	Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies
28 March 2026	Alexandra Boer Kimball	Sonelokimab in moderate-to-severe HS: Long-term results through Week 40 of two Phase 3 trials
28 March 2026	Benjamin Kaffenberger	Vilobelimab Treatment for Ulcerative Pyoderma Gangrenosum: Results from a Multicenter, Randomized, Placebo Controlled Phase 3 Trial
28 March 2026	Victoria P. Werth	Efficacy and Safety of Litifilimab in Cutaneous Lupus Erythematosus (CLE): 24-week results of the Phase 2 Study, AMETHYST Part A
28 March 2026	Arthi Thyagarajan	Clinical Characteristics and Treatment Outcomes of Juvenile Vulvar Lichen Sclerosus: A Retrospective Cohort Study
All Days	Vivian Shi	Four-year efficacy of continuous secukinumab in SUNSHINE/SUNRISE core and extension trials on hidradenitis suppurativa (HS) lesions



Notable Presentations Information At AAD 2026



Hair, scalp, nail, acne, rosacea, and aesthetic dermatology (1/4)

Date	Author	Title
27 March 2026	Li Ye	a-Arbutin Compound Formula for Melasma in Sensitive Skin: In Vitro Mechanisms & Randomized Trials
27 March 2026	Arash Mostaghimi MD	Early improvement in scalp hair regrowth with deuruxolitinib in patients with severe alopecia areata: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials
27 March 2026	Ana Melian-Olivera	Cosmetic Product Use and Risk of Frontal Fibrosing Alopecia in Men: A Case-Control Study
27 March 2026	-	Efficacy Study of a Novel Serum Containing Panthenol, Sphingomonas xenophaga Extract, and Bifidobacterium Fermentation Lysate for Use After Non-Ablative Picosecond Laser Treatment
28 March 2026	Roshni Sabhaya	Racial and Ethnic Disparities in Rosacea Clinical Trials
28 March 2026	Susan Ball	Real-world Effectiveness of Baricitinib for Severe Alopecia Areata by Baseline Hair Loss and Episode Duration: Results from a Prospective Observational Study
28 March 2026	Brett King	Long-term efficacy, complete scalp hair regrowth, and normal body hair and nails in patients with alopecia areata (AA) receiving ritlecitinib 50 mg once daily up to 3 years in the ALLEGRO clinical trial program
28 March 2026	Guilherme Kuceki	Adjunctive Combined Regenerative Technique (CRT) vs Oral Minoxidil Alone for Androgenetic Alopecia: A Six-Month Retrospective Study



Notable Presentations Information At AAD 2026



Hair, scalp, nail, acne, rosacea, and aesthetic dermatology (2/4)

Date	Author	Title
28 March 2026	Raymond Ezzat BS	Infections and Therapy Lapses Predominate as Flare Triggers on Oral JAK Inhibitors for Alopecia Areata: A Retrospective Cohort Study
28 March 2026	Woraphong Manuskiatti M.D.	Efficacy and safety of a 675-nm dual-mode laser for melasma in Fitzpatrick skin types III-V: A prospective study
28 March 2026	David Rosmarin	Novel Regulatory T-cell enhancing Biologic Rezpegaldesleukin: Phase 2b Efficacy and Safety Results Following 36-Weeks of Therapy in Severe-to-Very-Severe Alopecia Areata
28 March 2026	Shivani Gahlot	A Comparative Study on the Efficacy and Safety of Fractional CO2 Laser-Assisted Delivery of Methotrexate Versus Triamcinolone Acetonide in the Treatment of Patchy Alopecia Areata
28 March 2026	Abhijeet Kumar Jha	Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia: A Randomized, Single-Blind, Controlled Trial
28 March 2026	Neil S. Sadick	Efficacy and Mechanistic Insights of 1565 nm Fractional Non-Ablative Laser Therapy in Androgenetic Alopecia: A Prospective, Randomized Clinical and Histologic Study
29 March 2026	Derek Maas BS	Time Burden of Scarring Alopecias: A Scarring Alopecia Foundation Cicatricial Alopecia Patient Assessment & Impact Report Survey Study
30 March 2026	Christopher Thang	Benzoyl peroxide for acne treatment is not associated with an increased risk of malignancy: a retrospective cohort study



Notable Presentations Information At AAD 2026



Hair, scalp, nail, acne, rosacea, and aesthetic dermatology (3/4)

Date	Author	Title
All Days	Alicia Baez	Acne in Adulthood: A Study of Contributing Hormonal, Dietary, and Environmental Factors in Adults in Puerto Rico
All Days	Erin McKenzie B.S.	Case Control Study: Acne Prevalence and Severity May be Influenced by Maternal Age and Title IX
All Days	Ju Hee Han MD	Optimizing Acne Management with Dermocosmetics: A Clinical Equivalence Study of Monotherapy versus Combination Therapy to Facilitate Personalized Treatment Strategies
All Days	Natalia Kovyilkina	A randomized, placebo-controlled study evaluating the efficacy of a dermocosmetic serum containing 2-Mercaptanicotinyl Glycine (2MNG) in acne-induced post-inflammatory hyperpigmentation
All Days	Zoe D. Draelos MD	Long-Term Efficacy and Tolerability of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% (CAB) Gel for Acne in Participants With Fitzpatrick Skin Phototypes IV-VI: Pooled Results From Two 6-Month Studies
All Days	Nicholas Gulati MD	Association Between Biologic Therapy and Acne Treatment Escalation Among Patients with Inflammatory Acne: A TriNetX Database Study
All Days	Courtney Smith MS	Oral doxycycline dosing and treatment pathways in acne: A multi-center cohort study, 2010-2022
All Days	James Del Rosso DO	Efficacy of sarecycline in the treatment of moderate-to-severe facial acne vulgaris (AV): Combined results from three phase 3 studies



Notable Presentations Information At AAD 2026



Hair, scalp, nail, acne, rosacea, and aesthetic dermatology (4/4)

Date	Author	Title
All Days	Caitlyn Curley M.S. and Erum Ilyas M.D.	Depression and Anxiety Risk in Acne Patients with PCOS Treated With Oral Contraceptives and/or Spironolactone: A 5-Year Retrospective Cohort Study using the TrinetX database
All Days	Hongling Zhu	Clinical Efficacy of Small-Molecule Peptides in Anti-Aging for Sensitive Skin: A 6-Month Study
All Days	Li Ye	Based on PDRN and Ionic Liquid-Treated Botulinum-Like Peptide: Periorbital Anti-Wrinkle and Firming Efficacy and Implications for Aesthetic Anti-Aging Solution Selection — A Randomized Half-Face Controlled Study
All Days	Li Ye	Fibronectin in Post-Aesthetic Procedure Skin Barrier Repair: A Clinical Efficacy Study
All Days	Glynis Ablon MD	The influence of age on relabotulinumtoxinA outcomes in moderate-to-severe glabellar and lateral canthal lines: post-hoc analysis of three Phase 3 double-blind, placebo-controlled trials
All Days	Wilailuck Phokai	The study to evaluate efficacy and safety of combined of high, medium and low molecular weight hyaluronic acid for hand rejuvenation



Notable Presentations Information At AAD 2026



Skin cancer, dermatologic surgery, and oncologic diagnostics (1/4)

Date	Author	Title
27 March 2026	Umayr Shaikh MPH	Racial and Ethnic Disparities in Surgical Management of Vulvar Squamous Cell Carcinoma In Situ: A Surveillance, Epidemiology, and End Results (SEER) Outcomes Analysis (2000–2022)
27 March 2026	Leona Jafari OMS-III	A Retrospective Study on the Effects of Coal Tar on Melanoma Incidence
27 March 2026	Adilson DaCosta MD	Comprehensive Study of Childhood Melanoma Focusing on Survival, Histopathological, Immunoprofile, and Clinical Staging: A Retrospective, Single-Center, and Retrospective-Cohort Study of 55 Cases
27 March 2026	Aditya Dutt BS	Analyzing Acral Lentiginous Melanoma Time-to-Treatment Measures by Race and Ethnicity: A Surveillance, Epidemiology, and End Results (SEER) Database Study
27 March 2026	Mitchell Taylor MD	Characterizing Rural Disparities in Penile Squamous Cell Carcinoma Outcomes: A Nationally Representative Cohort Study
28 March 2026	Chunghwan Ro	Assessment of incident cutaneous squamous cell carcinoma among patients with hidradenitis suppurativa: A retrospective cohort study
28 March 2026	Jonathan C. Hwang BS	Incidence of Acral and Cutaneous Melanoma in the Veterans Affairs Cancer Registry and in the Surveillance, Epidemiology, and End Results Program
28 March 2026	Benjamin Hu BS	Outcomes in Kaposi Sarcoma Patients by Metropolitan, Suburban, and Rural Residence: A Surveillance, Epidemiology, and End Results (SEER) Study



Notable Presentations Information At AAD 2026



Skin cancer, dermatologic surgery, and oncologic diagnostics (2/4)

Date	Author	Title
28 March 2026	Nicholas Gulati MD	Real-World Risk of Keratinocyte Carcinoma in Atopic Dermatitis Patients Treated with Ruxolitinib 1.5% Cream: A TriNetX Database Study
28 March 2026	Catalina Axpe Gil	The Slow Mohs "Spaghetti" Technique in Melanoma: Results of a Retrospective Series from a Tertiary Care Center
28 March 2026	Kate Woods BS	Exploring Predictors of Surgery Refusal among Acral Lentiginous Melanoma Patients: A Nationally Representative Cohort Study
28 March 2026	Anisah Alladeen BS *These authors contributed equally to this research item	Characterizing Factors Associated with Mohs Micrographic Surgery Surgical Site Infections in Immunosuppressed Stem Cell Transplant Patients: A Retrospective Study
28 March 2026	Jose Ricardo	Nail unit squamous cell carcinoma: A multicenter, retrospective study of the clinical and morphologic characteristics of 261 patients.
28 March 2026	Helen Marsden	Diagnostic Performance of a Skin Cancer Detection AI Medical Device: A Prospective Clinical Validation Study and Repeatability and Reproducibility of a Skin Cancer Detection AI Medical Device: A Diagnostic Study
28 March 2026	Mary C. Spellman	PD-1 Directed Intratumoral Immunotherapy: Results of an Escalating Dose Study of INTASYL PH-762 for Cutaneous Carcinomas
29 March 2026	Mavra Masood MD	Skin Microbiome Shifts in Basal Cell Carcinoma: A Pilot Whole-Genome Sequencing Study



Notable Presentations Information At AAD 2026



Skin cancer, dermatologic surgery, and oncologic diagnostics (3/4)

Date	Author	Title
30 March 2026	Shima Ahmady	Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in treatment of Bowen's disease: A multicenter randomized controlled trial
30 March 2026	Lukas Flatz	Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single-institutional cohort study
All days	Benjamin Hu BS	An Updated Prevalence and Incidence Rate Report of Cutaneous Squamous Cell Carcinoma: A TriNetX Database Study
All days	Sebastian Beller B.S.	CTCL Outcomes in American Indian/Alaska Native vs. White Patients: A Matched Cohort Study
All days	Aditya Dutt BS	Comparing Oral Squamous Cell Carcinoma Time-to-Treatment Measures by Race and Ethnicity: A Surveillance, Epidemiology, and End Results (SEER) Database Study
All days	Victoria Hoffman MS	5-Fluorouracil Use After the Veterans Affairs Keratinocyte Carcinoma Chemoprevention Study
All days	Curtis Tam BS	Inverse Association Between Familial Adenomatous Polyposis And Skin Cancer: Evidence From a Large Cohort Study
All days	Benjamin Hu	Evaluating Relative Survival across Intersectional Demographics in Cutaneous Lymphoma Patients from the Surveillance, Epidemiology, and End Results (SEER) Database



Notable Presentations Information At AAD 2026



Skin cancer, dermatologic surgery, and oncologic diagnostics (4/4)

Date	Author	Title
All days	Sabine Steinke	Stigmatization Experiences and Psychosocial Burden in Cutaneous T-Cell Lymphoma Pa-tients: A Qualitative Study
All days	Sarah Lange BA	Patterns of Stage Migration in Mycosis Fungoides: A Retrospective Cohort Study of Upstaging, Downstaging, and Clinical Outcomes
All days	Mohammad Saad Farooq MD	Revisiting the Multicenter Selective Lymphadenectomy Trial-I in the modern era: undergoing sentinel lymph node biopsy is associated with overall survival benefit in cutaneous melanoma
All days	Talya Cohen-Neamie BA and Dr. Michael Kwa MD	Assessment of the Acral Melanoma ICD-10 Diagnosis Codes: A Validation Study
All days	Noa Kremer N.K	Demographic and Tumor Characteristics of Lentigo Maligna and Lentigo Maligna Melanoma for Presurgical RCM Mapping: A Retrospective Study
All days	Roberta Giuffrida Giuffrida MD	The influence of age, sex, localization, and morphology on the recurrence rate of lentigo maligna and lentigo maligna melanoma: an international, multicenter, retrospective study





Key Industry Sponsored Sessions Information



AAD 2026 Key Industry Sponsored Sessions Information (1/2)

Date	Author	Title
27 March 2026	SkylineDx	Latest Advances in Gene Expression Profiling (GEP) and GEP Guideline Updates for Cutaneous Melanoma
27 March 2026	DISC Medicine	Getting to the core of EPP and XLP: Understanding, diagnosing, and managing erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP)
27 March 2026	CP Skin Health	Innovations in Acne and Pigment Care: Therapeutic Photoprotection and the Synergy of Microneedling with Controlled Chemical Resurfacing
27 March 2026	Eli Lilly	Long-Term Disease Stability with Antibody Monotherapies in Moderate-to-Severe Atopic Dermatitis
27 March 2026	Lumenis	Ablative Resurfacing Masterclass: Clinical Pearls for Superior Outcomes
27 March 2026	AbbVie	Raising the Bar
27 March 2026	CLASSYS	Beyond Traditional RF: Safety and Efficacy of Everesse's Innovative Water-cooling System
27 March 2026	Pelthos Therapeutics	Challenging the Watch-and-Wait Paradigm: Introducing Zelsuvmi™ (berdazimer) topical gel, 10.3%





AAD 2026 Key Industry Sponsored Sessions Information (2/2)

Date	Author	Title
28 March 2026	Abbvie	Sailing into Clear Horizons
28 March 2026	RoC Skincare	Evaluating the Role of RoC Retinol in Skin Longevity
28 March 2026	Eli Lilly	Explore EBGLYSS®(lebrikizumab-lbkz)
28 March 2026	Novartis	Now Approved: A new path forward with RHAPSIDO® (remibrutinib)
29 March 2026	Galderma	Targeting the IL-31 Neuroimmune Pathway: A Case-Based Approach
29 March 2026	Thermo Fischer Scientific	Novel Discovery to Clinical Dermatology: Tregs in Inflammatory Skin Diseases
29 March 2026	Eli Lilly	A Product Theater for Taltz® (ixekizumab) and Zepbound® (tirzepatide) Injection including an Affordability Program for Eligible Taltz Patients Prescribed Zepbound
29 March 2026	Sanofi	Illuminating the Inflammatory Prequel in Atopic Dermatitis
29 March 2026	Doximity	AI for Dermatologists: Optimizing Clinical Workflows with Doximity GPT





Noteworthy AI / ML presentations at AAD 2026





Themes from key AI / ML presentations at AAD 2026 (1/2)

- **AAD 2026 AI/ML content will signal a shift from novelty to implementation, with strongest momentum in diagnostic support, patient education, and workflow tools, while bias, trust, and validation gaps remain the main barriers to broader dermatology adoption**
- Check out the key AI / ML themes at AAD 2026 below:
- **Diagnostic AI will dominate:**
 - AAD 2026 AI/ML content will center on diagnosis across skin cancer, dermoscopy, dermatopathology, nail disease, inflammatory dermatoses, and darker phototypes, signaling the strongest concentration of applied-use cases
- **Equity gaps will remain central:**
 - Multiple titles will focus on skin tone, sex representation, Fitzpatrick V–VI performance, and darker phototypes, indicating bias, dataset imbalance, and generalizability will emerge as leading analytical concerns
- **Psoriasis will anchor image analytics:**
 - Psoriasis studies will emphasize remote severity assessment, lesion identification, segmentation, and visualization, suggesting AI/ML will advance beyond detection toward monitoring, quantification, and patient-facing disease tracking



Themes from key AI / ML presentations at AAD 2026 (2/2)

- **Skin cancer tools will drive validation:**
 - Skin cancer detection, keratinocyte carcinoma classification, melanoma education, and AI-powered dermoscopy will stand out, while only one prospective clinical validation title will suggest limited late-phase validation depth
- **Generative AI will expand education workflows:**
 - GPT-4, GPT-4o, translation tools, ambient scribing, and patient education platforms will position generative AI as a workflow and communication enabler rather than a purely diagnostic technology
- **Trust and implementation will shape adoption:**
 - Patient perspectives, demographic predictors of acceptance, coverage decisions, and residency education will show that adoption barriers will extend beyond accuracy into trust, governance, reimbursement, and workforce readiness
- **Wound and chronic care AI will broaden scope:**
 - Wound area assessment, tissue composition analysis, and healing trajectory prediction will indicate AI/ML expansion into longitudinal care, where repeated measurement may matter more than single-visit classification



Noteworthy AI / ML presentations at AAD 2026

Notable Presentations At AAD 2026

AI / ML (1/4)



Date	Author	Title
28 Mar 2026	Mina Farah BA	Identifying High-Risk Factors for Sensitive Skin Through Artificial Intelligence: A Cross-Sectional Analysis
28 Mar 2026	Lauren Ling BS	Patient Perspectives on AI Ambient Scribing in an Academic Dermatology Practice
28 Mar 2026	Krithika Nayudu	Representations of Skin Tone and Sex in Pediatric Dermatologic Diagnoses: An Evaluation of Generative Artificial Intelligence
28 Mar 2026	Julianna Tolotta BS	Improving Spanish Dermatology Education: Readability Comparison of AI Translations
28 Mar 2026	Adam Kashlan B.S.	Artificial Intelligence-Based Prediction of Dermatology Residency Interview Success
28 Mar 2026	Sharif Amit Kamran Ph.D.	Attention-Based Masking Artificial Intelligence Architecture for Remote Psoriasis Severity Assessment
28 Mar 2026	Helen Marsden	Diagnostic Performance of a Skin Cancer Detection AI Medical Device: A Prospective Clinical Validation Study and Repeatability and Reproducibility of a Skin Cancer Detection AI Medical Device: A Diagnostic Study
28 Mar 2026	Faranak Kamangar	Pearls in Artificial Intelligence Applications in Dermatology

Notable Presentations At AAD 2026

AI / ML (2/4)



Date	Author	Title
28 Mar 2026	Lynn C. Cheng	Unclick the Clinic: The AI Revolution
29 Mar 2026	Caryn Etkin	Leveraging AI for Comprehensive HS Education Initiatives
29 Mar 2026	Ashish Bhatia	Artificial Intelligence in Aesthetics and Laser Medicine: The Next Frontier
30 Mar 2026	Yevgeniy Semenov	Brave New Worlds: Embracing AI & Balancing Risks
All Days	Jessica Pixley MD	A comparison of facial skin characteristics between day- and night-shift workers using a validated artificial intelligence assessment tool
All Days	Thibault Maho and Bryan Boule	Advancing Ethical AI in Dermatology: A Fitzpatrick Skin Type Classifier to Prevent Diagnostic Bias
All Days	Zaim Haq	Evaluating Multimodal AI for Dermatopathology Image Interpretation: A First Look
All Days	Precious Ochuwa Imokhai BS	A Systematic review of artificial intelligence performance for post-inflammatory hyperpigmentation in Fitzpatrick skin types V–VI reveals persistent diagnostic blind spots and insufficient bias-mitigation strategies

Notable Presentations At AAD 2026

AI / ML (3/4)



Date	Author	Title
All Days	Nawar Tarafdar BSc	Predictive Performance of Machine Learning Models for Biologic Treatment Response in Patients with Psoriasis and Psoriatic Arthritis: A Systematic Review
All Days	Grace Herrick BA	Artificial Intelligence for Patient Education in Dermatology: A Systematic Review of Interactive Tools
All Days	Lily Mikolajczak BS	AI Visualization and Severity Analysis Decreases Patient Distress and Anxiety While Patient Perception of AI Remains Unchanged
All Days	Hafsa Hassan BS	Artificial Intelligence as Both Barrier and Advocate in Dermatologic Coverage Decisions
All Days	Ahmad Alamari AA	Identification and Segmentation of Psoriasis Lesions Using Skin Images: A Systematic Review and Meta-Analysis of Machine Learning and Artificial Intelligence Models
All Days	William J. Nahm BA	Deep Learning Dichotomous Classification of Inflammatory Changes in Keratinocyte Carcinomas Treated with Topical Therapy with Imiquimod, 5-fluorouracil, and Retinoids
All Days	Nathaniel Bunnell BA	Artificial Intelligence Education in Dermatology Residency: A Needs-Based Assessment of Nationwide Programs
All Days	Ashesh Desai MD Candidate	AI-Powered Dermoscopy: Deep Learning Accurately Differentiates Basal Cell Carcinoma and Dermatofibroma

Notable Presentations At AAD 2026

AI / ML (4/4)



Date	Author	Title
All Days	Samia Rahman MD	Diagnostic Accuracy of AI in Dermatology for Skin of Colour: A Systematic Review and Meta-analysis
All Days	Aniket Asees BA	Who Trusts the Machine? The Impact of Demographic Predictors on Acceptance of AI in Dermatology
All Days	Sydney Wolfe B.A.	Leveraging Emerging AI Models for Melanoma Education: Comparing GPT-4 vs. GPT-4o Readability
All Days	Kiratpreet Sraa B.S.	Artificial Intelligence in Nail Disorder Diagnosis: A Review of Image-Based Models for Remote and Reliable Triage
All Days	yosr	The Efficacy of Artificial Intelligence Powered Software in Enhancing Diagnostic Accuracy: An Image-Based Study of Skin Diseases in Darker Phototypes
All Days	Samantha Bestavros HBSc	Enhancing Wound Analysis with Artificial Intelligence: A Point-of-Care Tool for Assessing Wound Area and Tissue Composition
All Days	Ashesh Desai MD Candidate	Application of Machine Learning to Predict Healing Trajectories in Chronic Wound Care



Strategic Insights and Strategy Development is our focus

COMPETITIVE STRATEGY
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VACCINES & INFECTIOUS
DISEASES



INVESTMENT INSIGHTS

e: INFO@LQVENTURES.COM

w: WWW.LQVENTURES.COM